Health News

Tralokinumab Gets Nod for Atopic Dermatitis in Europe

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the IL-13 inhibitor tralokinumab (Adtralza) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are eligible for systemic therapy. The new opinion represents the final stages before the European Commission decides […]